Learning from logic.
And from each other.

Dylan is a 17-year-old scientist and founder co-advised by Dr. Chris Mason of Sun Vectors and University College London, and Helena Rosengarten of Axonic. He previously conducted independent, cancer-focused genetic circuit research that advanced him to the International Science and Engineering Fair, where he was selected as a finalist by the Society for Science under Regeneron.

Dylan has performed wet-lab research at Johns Hopkins University under Sara Ho and at the Baltimore Underground Science Space under Dr. Peter Evans and Dr. Lisa Scheifele, working across synthetic biology systems. He is the inventor of GenCTX's very own GC-Therapy.

Dylan is a fellow at Emergent Ventures, a 1517 Fund Medici Grant awardee, and a two-time International Genetically Engineered Machines Competition medalist. Dylan's father is a cancer survivor, which motivates his pursuit of curative therapies.

Peter is a molecular biologist and scientific leader whose career centers on building rigorous, decision-grade biological systems at the intersection of genomics, regulation, and real-world deployment.

He spent much of his career at the U.S. Food and Drug Administration as a Branch Chief, where he oversaw large, mission-driven research programs applying molecular biology and whole-genome sequencing to high-stakes biological questions, translating complex data into standards and policy.

Peter brings deep experience in experimental design, data rigor, and scientific governance - the skills required to turn advanced biological concepts into reproducible, defensible systems. From 2014 to 2022, he served as a co-convenor for the International Organization for Standardization, leading the development of ISO 23418 for genomic characterization, demonstrating his ability to define what "good science" looks like when it must scale, withstand scrutiny, and guide real decisions.

Yil is a gene therapy scientist with over 15 years of experience advancing viral and non-viral gene transfer technologies from early research through IND-enabling development.

He most recently served as Associate Director of Transgene Biology and Genomics at Moderna, where he led teams designing mRNA and DNA constructs, developing mRNA-based virus-like particle platforms, and building bioanalytical assays to support novel gene transfer tools.

Previously, Yil held senior scientific and leadership roles at AVROBIO, directing preclinical proof-of-biology studies and advancing lentiviral gene therapies for rare diseases including Fabry, Pompe, and Hunter, while supporting regulatory filings and CRO execution. Earlier in his career, he conducted stem cell, epigenetics, and cancer research at Memorial Sloan Kettering Cancer Center.

Yil earned his Ph.D. in Biology from Leibniz University Hannover and is a named inventor on widely used lentiviral vector tools and gene therapy-related patents.